CFAH The 12th annual WIN Symposium 2022: a scientific program par excellence – VHIO – Vall d'Hebron Institute of Oncology

The 12th annual WIN Symposium 2022: a scientific program par excellence

Co-chaired by VHIO’s Director, Josep Tabernero, and Richard L. Schilsky, Chairman of the WIN Consortium, the 12th annual WIN Symposium themed Integrating Genomics and Transcriptomics to Reshape Precision Oncology: A WINning Strategy, is coming to Barcelona 14-15 March, 2022.

The superb scientific agenda, expertly assembled by this two-day meeting’s Scientific Committee, features some 30 renowned leaders in translational research, clinical oncology and personalized cancer medicine from academia, industry and research organizations, who will present and discuss the very latest advances in cancer discovery from across the globe.

Kicking off with WIN 2022’s Opening Keynote Lecture, Re-imaging the (r)evolution in the Precision Oncology paradigm: the future is now, to be delivered by Vivek Subbiah, Associate Professor and Medical Director of the Clinical Center for Targeted Therapy, University of Texas MD Anderson Cancer Center (TX, USA), the program offers an exciting lineup of Keynote, Plenary, and Meet the Expert sessions followed by discussion panels and Q&A exchange between speakers and symposium participants.

In addition, Session 4: WIN’s First International Molecular Tumor Board: a Strategic Place in Advancing Precision Oncology, moderated by Razelle Kurzrock, Chief Medical Officer of the WIN Consortium, and Director, Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center (CA, USA), will present WIN members’ patient populations across the world followed by discussion with the audience.

“By bringing all critical stakeholders in oncology together under one roof, WIN 2022 will continue to build on the successes of meetings past. As Symposium Co-Chair, I can promise all participants the very latest advances in precision oncology that are increasingly being driven by genomics, transcriptomics, imaging and artificial intelligence,” said Josep Tabernero, VHIO’s Director and Head of the Vall d’Hebron University Hospital’s (HUVH) Medical Oncology Department.

He continued, “Our outstanding panel of eminent speakers will also provide us with the very latest insights generated by translational and clinical research of excellence, as well as novel treatment strategies and approaches aimed at more effectively combating several tumor types.”

A trio of VHIO contributions at WIN 2020

WIN 2020’s Scientific Program will also count on the expertise of VHIO researchers and clinical investigators. Josep Tabernero will follow the two Keynotes, Session 2, delivered by Andrea Califano, Professor of Biomedical Informatics, Columbia University Medical Center (NY, USA) and Richard L. Schilsky, Professor Emeritus, University of Chicago (IL, USA).  During this second session on Innovation in Clinical Trials to Enable Future Efficient Treatments, Monday March 14, Josep will present on genomic transcriptomic signatures and innovation in colorectal cancers.

On Tuesday March 15, VHIO’s Enriqueta Felip, Principal Investigator of our Thoracic Tumors & Head and Neck Cancer Group, will focus on neoadjuvant and adjuvant strategies against non-small-cell lung cancer (NSCLC), during the Meet the Experts on Disruptive Concepts and Methodological Innovations in NSCLC. Solange Peters, Head of the Medical Oncology Service, University Hospital of Lausanne – CHUV (Switzerland), and President of the European Society of Oncology (ESMO), 2020-2022, will commence Session 3 with her Keynote Lecture on Advances in Lung Cancer.

During Session 5, What is New in Breast, CRC, Ovary, Head & Neck, Prostate, Kidney, Pediatric Cancers?, Tuesday March 15, Joaquin Mateo, Principal Investigator of VHIO’s Prostate Cancer Translational Research Group, will deliver an expert talk on Expanding Precision Oncology across Tumor Types: advances in prostate cancer. Opening this session, Keynote Speaker Martine Piccart, Scientific Director of the Jules Bordet Institute (Brussels, Belgium), will present the first results of the Breast International Group’s (BIG) AURORA molecular screening program for metastatic breast cancer.

“Endorsed by the American Society of Clinical Oncology, our annual WIN Symposia represent must-attend meetings and also provide unparalleled opportunity to interact with world class leaders who are trailblazing precision oncology across borders. I very much look forward to welcoming you all to Barcelona for this two-day celebration of personalized cancer medicine,” concluded Josep Tabernero, who also serves as Chair of WIN’s Scientific Advisory Board.

To access the WIN Symposium 2022 full Scientific Program please click here.

PLEASE NOTE: Abstract submission and online registration will soon be open. For further announcements and updates we invite you to bookmark: https://www.winsymposium.org/symposium/.

 

###

29/10/2021|Tags: , |